Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials

Canadian Journal of Gastroenterology

Volumn 20, Issue 2, 2006, Pages 87-90

  Kaita, Kelly D E ^a,b   Wong, Stephen ^a,b   Renner, Eberhard ^a,b   Minuk, Gerald Y ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Health Sciences Centre   (Canada)

Author keywords

HCV therapy; Hepatitis C; Hepatitis C virus; Outcomes

Indexed keywords

AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; CANADA; CHRONIC HEPATITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HEART DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URBAN AREA; VALIDATION PROCESS; VIRUS LOAD;

EID: 33645305121     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/148962     Document Type: Review

References (19)

1. Guffreund KS, Bain VG. Chronic viral hepatitis C: Management update. CMAJ 2000;162:827-33.
2. Remis R, Hogg R, Krahn MD, Preiksaitis JK, Sherman M. Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-85 and 1990-92. Report to Health Canada. Ottawa; Public Works and Government Services Canada, 1998.
3. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Oastroenterol 2000; 14:575-80.
4. Deuffic-Burban S, Wong JB, Vatleron AJ, Costagliola D, Delfraissy Jf, Poynard T Comparing the public health burden of chronic hepatitis C and HIV infection in France. j Hepatol 2004;40:319-26.
5. Wong JB, McQuillan GM, McHutchison JG, Poynard T Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
6. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20-9.
7. Di Bisceglie AM, Hoofnagle JH. Therapy of chronic hepatitis C with (α-interferon: The answer? Or more questions? Hepatology 1991; 13:601-3.
8. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon (α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
9. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
10. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
11. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
12. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
13. Manus MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
14. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
15. Sherman M, Bain V, Villeneuve J-P, et al. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis 2004;15:313-26.
16. Sherman M. Management of viral hepatitis: Clinical and public health perspectives - a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver. Can J Gastroenterol 1997;11:407-16.
17. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
18. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration. Cleve Clin J Med 2004;71 (Suppl 3):S8-12.
19. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92.